Integrated needle-free injection and sensing using opto-microfluidics

iSENS is developing BoldJet, a portable needle-free injector using thermocavitation microjets for precise, safe, and environmentally friendly medication delivery, enhancing patient compliance and healthcare outcomes.

Subsidie
€ 2.499.999
2024

Projectdetails

Introduction

Needle-based injections have revolutionised healthcare by providing an efficient delivery method for medications, such as vaccines. However, there are significant drawbacks associated with using needles on a societal, environmental, and technological level.

Challenges of Needle Use

  • Needle Phobia and Infection Risks: Needle phobia and infection risks can significantly impact patient compliance and safety with medical treatments.
  • Environmental Contamination: Millions of used needles contaminate the environment every day.
  • Injection Effectiveness: The effectiveness of certain drugs increases when injected intradermally, but targeting the dermis is challenging.

Project Overview

With iSENS, we want to revolutionise the experience of people who receive and perform frequent injections. To this end, we are developing and commercialising a portable and needle-free injector called BoldJet.

Technological Breakthroughs

Our technological breakthrough is threefold:

  1. Needle-Free Injection Breakthrough: We introduce an innovative needle-free injection technology, globally pioneering the use of thermocavitation microjets. Our system excels in the precise and consistent delivery of liquids into the skin's superficial layers, surpassing current state-of-the-art methods.

  2. Smart Sensing Capability: The BoldJet device will incorporate cutting-edge sensing technology, enabling it to assess the unique properties of the patient's skin before each injection. This breakthrough allows for semi-automatic calibration, tailoring the injection parameters to the specific skin type and treatment area.

  3. Real-Time Monitoring and Precision: BoldJet goes beyond conventional methods by offering real-time monitoring of injection depth and volume. This feature guarantees that each dose is administered accurately and consistently.

Conclusion

With our triple technology platform, we will offer safer, more effective, and minimally invasive injections that do not contaminate our environment. This patient-friendly technology will result in a positive effect on society, allowing millions of people to receive better and more personalised healthcare.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.499.999
Totale projectbegroting€ 2.512.500

Tijdlijn

Startdatum1-7-2024
Einddatum30-6-2027
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • FLOWBEAMS BVpenvoerder

Land(en)

Netherlands

Vergelijkbare projecten binnen EIC Transition

EIC Transition

Targeting cardiac fibrosis with next generation RNA therapeutics

FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.

€ 2.499.482
EIC Transition

automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS

The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.

€ 2.497.750
EIC Transition

Predictive REagent-Antibody Replacement Technology stage 2-Translation

PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.

€ 800.000
EIC Transition

Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage

Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.

€ 2.499.810

Vergelijkbare projecten uit andere regelingen

ERC POC

Skin micro-injector

Bold-Jet aims to revolutionize needle-free injections with a microjet device that enhances safety, minimizes invasiveness, and improves patient adherence to treatments.

€ 150.000
ERC POC

Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantification

This project aims to validate the BuBble Gun injection method using Skin-On-Chip technology for localized drug testing in chronic skin diseases, paving the way for innovative treatment delivery.

€ 150.000
EIC Accelerator

AmbiJet: the world’s first and only highly effective plasma-based solution for Europe’s 16 Million periimplantitis patients urgently needing help to avoid losing their dental implant

AmbiJet is a groundbreaking plasma-based technology that effectively eliminates bacteria on dental implants, preventing reinfection and promoting better oral and overall health.

€ 1.389.062
MIT Haalbaarheid

NEW PRODUCTION METHOD OF INJECTABLE MICROCAPSULES FOR PULSATILE VACCINE DELIVERY

IamFluidics onderzoekt de haalbaarheid van 'in-air microfluidics' voor het produceren van polylactic acid microcapsules voor gecontroleerde vaccinafgifte, met als doel een kosteneffectieve, pulsatile injectieoplossing.

€ 20.000